Clinical Trial Update: Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context [NA]

View source ↗

Summary

A clinical trial update announcing the ongoing recruitment of a real-world study evaluating lorlatinib in untreated ALK-positive non-small cell lung cancer pati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alk-positive Non-small Cell Lung Cancer

Drugs mentioned

• lorlatinib (lorlatinib)

Snippet

Sponsor: Pfizer | Conditions: ALK+ Non-Small-Cell Lung Carcinoma | NA | Status: RECRUITING